Active Surveillance of Adverse Drug Reaction and Its Development Trend

[1]

JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.

[2]

ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.

[3]

ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing. Advances in studies on post-market safety data sources and signal detection for medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.

[4]

WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.

[5]

SUN Yixin, LIU Zhike, ZHAN Siyan. Scoping review of near real-time surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.

[6]

LIU Zhike, ZHAN Siyan. Progress in applications of self-controlled designs in association study of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.

[7]

CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi. Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.

[8]

WANG Yi, REN Jingtian. Evaluation and significance of benefit-risk analysis of benzbromarone-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 189-192.

[9]

YU Hongli, PANG Yu, SHAO Bo, XIAO Aili, YU Dongmei. Current Adverse Drug Reaction Reporting and Monitoring of Essential Medicines in China [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 766-768.

[10]

HOU Yongfang, SONG Haibo, LIU Hongliang, LI Xilin. Practice and Discussion on Active Surveillance by China Hospital Pharmacovigilance System [J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 212-214.

[11]

WANG Meng, GUO Xiaojing, YE Xiaofei, XU Jinfang, HU Fangyuan, HE Jia. Application of Bayesian Instrumental Variable in Active Surveillance Data of Adverse Drug Reactions:a Simulation Study [J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 139-143.

[12]

WANG Dan, LI Xinling, DONG Duo, XIONG Weiyi, LIU Cuili, ZHU Lan, GENG Fengying, LIAO Jianbo, YANG Yueming, LAN Shan, LV Xiaoqin, WANG Tongchun, ZHAO Xia, WANG Wen. Investigation of Pharmaceutical Manufacturers’ Ability of Direct Reporting of Drug Adverse Reactions [J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 654-661.

[13]

[14]

GUO Xiaojing, WANG Meng, GUO Wei, YE Xiaofei, ZHU Tiantian, HE Jia. Status and Challenges of Controlling Confounding Factors in Active Surveillance of Adverse Drug Reactions [J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 595-599.

[15]

CAI Ting, YANG Yu, WANG Ya-li, DONG Duo, ZHAN Si-yan. Review and Analysis of Active Post-marketing Surveillance Modes for Vaccine Safety [J]. Chinese Journal of Pharmacovigilance, 2017, 14(8): 464-469.

PDF (PC)